Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Cross-check your institutional ethics and COSHH requirements with your compliance officer before sourcing materials
In vitro research use only Not for human or animal use peptides PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist studied in MC3R/MC4R pharmacology and central nervous system signaling research
Always consult your prescriber before attempting any medication combination
Reduced adult hippocampal neurogenesis and cognitive impairments following prenatal treatment of the antiepileptic drug valproic acid
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
US$ 27.29
US$ 21.98
US$ 25.69
US$ 28.28
US$ 28.63
